Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiolabeled BC8 Antibody with Busulfan and Cyclophosphamide for AML in First Remission
NCT00005940Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Oct 1999
- Primary completion
- Jan 2006
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of apamistamab in acute myeloid leukemia (AML), sponsored by Fred Hutchinson Cancer Center. Started Oct 1999; status: completed.
02
Drugs
apamistamab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00005940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005940.